"The PP groups show a non significant difference, which is easily explainable by the massive differential in drop out rates between the two groups (80% vs 50%)"
There most certainly is more to say. What it tells you is that the reasons for the difference in outcome need to be explained, since it suggests that possibly many patients missed out on having optimum treatment. That treatment might well have extended their lives. Its very important not to simply dismiss it, it may well be the result of poor management or conduct of the study.
- Forums
- ASX - By Stock
- Ann: Soramic Clinical Study Results to be Presented at EASL/ILC
"The PP groups show a non significant difference, which is...
Featured News
Add SRX (ASX) to my watchlist
|
|||||
Last
17.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $74.27M |
Open | High | Low | Value | Volume |
17.5¢ | 17.8¢ | 17.5¢ | $51.74K | 295.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 2529419 | 17.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
18.0¢ | 2426769 | 38 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 2529419 | 0.175 |
9 | 10307688 | 0.170 |
1 | 18186 | 0.165 |
1 | 11500 | 0.155 |
1 | 2577 | 0.097 |
Price($) | Vol. | No. |
---|---|---|
0.180 | 2276769 | 37 |
0.185 | 114745 | 7 |
0.190 | 158362 | 6 |
0.195 | 505000 | 2 |
0.200 | 433737 | 9 |
Last trade - 16.10pm 14/08/2024 (20 minute delay) ? |
Featured News
SRX (ASX) Chart |